AN ANTIBACTERIAL COMPOSITION OF THIENAMYCIN-TYPE COMPOUND AND A DIPEPTIDASE INHIBITOR

Abstract: A novel antibacterial drug combination is provided, one component being a fused ring β-lactam, such as thienamycin and its semi-synthetic derivatives, and the other component is a dipeptidase (E.C. 3.4.13.11) inhibitor. The dual-component combination is formulated so that 1 to 3 parts by weight of the β-lactam compound are employed for 30 to 1 parts by weight of the inhibitor compound.

Description: TITLE OF THE INVENTION: An'Antibacterial Composition or ienamvoin-type Compound and a Dipeptidase Inhibitor. INTRODUCTION: A new class of fused ring g-lactam antibiotics, including thienamycin and its semi-synthetic derivatives, epithienamycins, and olivanic acids, has recently been described. These compounds which will be defined more extensively below, are hereinafter referred to as the wthienamycin class of compounds". These compounds have a high level of antibacterial activity, but are subject to extensive metabolism by mammalian species. The kidney was identified as the primary site of metabolism, and an enzyme was purified from renal extracts which catalyzed the inactivation of thiena mycin by hydrolysis of the ss-lactam. By such criteria as cytological localization, substrate specificity and susceptibility to enzyme inhibitors, this enzyme is very similar if not identical to a widely studied renal dipeptidase (E.C.3.4.13.11), also referred to in the literature as wdehydro- peptidase-I". However, the ss-lactamase activity is exhibited only toward the thienamycin class of compounds. Indeed, there exists no precedent example of the mammalian metabolism via ss-lactam cleavage of any representative of the classical &beta;-lactam antibiotics, the penicillins and cephalosporins. DETAILED DESCRIPTION OF THE INVENTION: THIENAMYCINS The term "thienamycin class of compounds" is used to identify any of a number of naturally occurring, semi-synthetic, or synthetic derivatives or analog compounds having a common fused-ring ss-lactam nucleus. These compounds can be generically classed as 6- and (optionally) 2-substituted pen-2-em-3-carboxylic acids and l-carbadethia-pen-2em-3-carboxylic acids or lazabicyclo 13,2.01hept-2- ene-7-one-2-carboxylic acids. Specific compounds particularly useful in this invention are represented structurally in the following formula I: EMI2.1 wherein X can be CH2 or St R2 can be hydrogen; 3 3 -S-CH2CH2NHR , wherein R3 is hydrogen, acetyl, formimidoyl, acetimidoylt -S(O)-CH=CHNSCOCHn and -S-CH=CHNHCOCH3; and R6 is EMI2.2 wherein 7 is hydrogen, hydroxy or sulfonyloxy, or R6 is H. All possible stereoisomeric forms are included within the above structural definition. All of these compounds within Formula I are described in the literature. When X is CH2, and R2 is SCH2CH2NH2, and R6 is CH(OH)CH3, the compound is known as thienamycin, an antibiotic produced by fermentation of S. cattleya, deposited as NRRL 8057 at Northern Regional Research Laboratories, U.S. Department of Agriculture, Peoria, Illinois, U.S.A., on November 18, 1974 described and claimed in U.S. Patent 3,950,357, issued April 13, 1976. The N-substituted derivatives of thienamycin, i.e., in the formula I above wherein R3 is other than hydrogen, are disclosed and claimed in co-pending U.S. applications and their published foreign equivalents. The fermentation product N-acetyl thienamycin (R6 is CH(OH)CH3, and R3 is acetyl), also called 924A, is claimed in Belgian Patent o. 8S,346, issued May 16, 1977. The N-imidoyl derivatives are covered in Belgian Patent No. 848,545, issued May 20, 1977. The unsaturated side chain-containing compound, also called N-acetyl-dehydrothienamycin or 924A5 is a fermentation product of S. cattleya, NRRL 8057 claimed in U.S. SN 788,491, filed April 18, 1977, Case 16022, now ¯ ¯¯¯¯ ¯ , and also in Belgian Patent No. 866,035, issued October 17, 1978. Epimeric forms of N-acetyl thienamycin, also called 890A, and 890A3, as well as the desacetyl 890A, and desacetyl 890A3 are disclosed, respectively in published French Appln. 763,887, filed November 19, 1976, with U.S. SN 63,3oo, filed U.S. priority of November 21, 1975, case 15745, and Belgian Patent 848,349, issued May 16, 1977. Epimeric forms of the unsaturated thienamycin, also called 890A2 and 8 90A5 are claimed in published French of April 28, 1976, Case 15839. 5he 6-sulfonyloxycontaining N-acetyl compounds, also called 890A9 or 890A10, are claimed respectiuely, in published French Appln. 7,734,456, filed November 16, 1977, with U.S. priority of November 17, 1976, Case 15935, and published French Appln. No. 7,734,457, filed November 16, 1977, U.S. priority of November 17, 1976, Case 15936. Desacetyl analogues of 890A9 and 890A10 are respectively claimed in U.S. SN 767,723, filed February 11, 1977; and DE-OS 28 05 701, and its continuation U.S. SN 860,665, filed December 15, 1977, now and also in French Appln. 7,803,666, filed February 9, 1978; and U.S. SN 767,920, filed February 11, 1977 ; and DE-OS 28 05-724, and its continuation U.S. SN 006,959, filed January 25, 1979, now ¯¯ ¯¯ , and also in French Appln. 7,803,667, filed February 9, 1978. Some of these latter compounds in the 890A9 and 890 A10 series are also known as derivatives of olivanic acid (see Corbett et al., J. Chem. Soc. Chem. Commun. 1977, No. 24, pp. 953-54). Compounds of the Formula I above when R2 is hydrogen, also called descysteaminyl thienamycins, are claimed in U.S. SN 668,898, filed March 22, 1976, Case 15866, now abandoned, and its continuation-in-part, U.S. SN 847,297, filed October 31, 1977, now abandoned, and also in Belgian Patent 867,227,.issued November 20, 1978. When R6 is hydrogen, and X is CH2, these compounds are disclosed in Case 15902, U.S. SN 843,171, filed January 1, 1977, and in its published German equivalent Off. 2,751,624.1, filed November 18, 1977. A thienamycin-type antibiotic in which R2 is -SCH2CH2NHAc and R6 is C2H5, has been named PS-5 and is reported by K. Okaimura et al., J. Antibiotics 31 p. 480 (1978), see also Belgian Patent 865,578. The compounds in which X is S, also called "penems", are described by R.B. Woodward in "Recent Advances in the Chemistry of B-tactam Antibiotics", J. Elks (Ed), The Chemical Society, London, 1977, p. 167t R.B. Woodward, Abstracts of Uppsala University 500 Years Symposium on Current Topics in Drug Research, Uppsala, Sweden, October 1921, 1977. Acta. Pharm. Suecica, Vol. 14, Supplement, p. 23, and U.S. Patent 4,070,477, issued January 24, 1978. Particularly preferred members within the thienamycin class of compounds are the N-formimidoyl and N-acetamidoyl derivatives of thienamycin. The crystalline form of N-formimidoyl thienamycin, which has recently been described, is also useful in the practice of this invention. An example illustrating a preferred way of making this compound follows: ILLUSTRATIVE EXAMPLE N-Formimidoyl thienamycin, cXystalline Step Ab Benzylformimidate hydrochloride A 3 1. three-necked flask fitted with an addition funnel, overhead stirrer, and a reflux condenser, was charged with a mixture of benzyl alcohol (125 g., 1.15 mol) formamide (51 g., 1.12 mol) and anhydrous ether (1200 ml.). The mixture was stirred vigorously at room temperature (20-250C) under a nitrogen atmosphere and benzoyl chloride (157 g., 1.12 mol) in 50 ml. of anhydrous ether was added dropwise using the addition funnel. The addition required approximately 50 minutes. The reaction mixture was stirred an additional 60 minutes at room temperature. The ether was removed by decantation and 300 ml. of acetic anhydride in 500 ml. of anhydrous ether was added. The mixture was stirred 30 minutes at room temperature. The precipitate was allowed to settle and the etheracetic anhydride was again removed by decantation. The solid was collected by filtration, washed with 500 ml. of ether and dried in vacuo over KOH at 250C for 2 hrs. to give 130 g. (67%) of benzylformizaidate hydrochloride as a white solid. The product was assayed by NMR S (DMSO) 5.7 (s, 2H, CH2), 7.5 (s, 5H, ), 9.0 (s, 1H, HC=N). The product is thermally unstable. It decomposes to formamide and benzyl chloride at 0 C and above. However, no appreciable decomposition was detected on storage at -200C for 2 months. Step B. Derivatization of Thienamycin Thienamycin (in the form of a 6 1. aqueous solution, pH = 6.5, concentrate from the fermentation broth, containing 28 g. thienamycin) was placed in a large beaker (12 1) and cooled to OOC. The beaker was equipped with a pH meter and an efficient high speed stirrer. The pH was raised to 8.5 by the careful addition of 3N KOH (KOH was added dropwise via syringe to the stirred solution). The solution was treated with 6 equivalents of solid benzyl formimidate hydrochloride (N100 g.) in portions while maintaining the pH at 8.5 + 0.3 by the addition of 3N KOH (200 ml.) using a syringe. The addition required 3-5 min. The reaction mixture was stirred for 6 min. at OOC and then assayed by liquid chromatography to insure completion of the reaction. The solution was adjusted to pH 7 with 1N HC1. The volume of the reaction mixture was measured, and the solution was assayed by UV. The neutralized reaction mixture was concentrated to 15 g./l. on the reverse osmosis unit at < 10 C. The volume of the concentrate was measured and the pH was adjusted to 7.2-7.4, if necessary. The concentrate was filtered through a medium porosity sintered glass funnel to remove any solids present after concentration. Step C. Dowex 50W x 2 Chromato;raphy The concentrate (750-1000 ml.., 15-20 g.) was applied to OOC. to a precooled 18 1. column of Dowex 50W x 2 in the potassium cycle (200-400 mesh resin) and the column was eluted at 0-50C with distilled deionized water a flow rate of 90 ml/min. and a head pressure of 0-45 psig. Forerun fractions of 4 1., 2 1., and one 1., were collected followed by 18 fractions of 450 ml. each, and one final fraction of 2 1. Each fraction was assayed by W (1/100 dilution, NH2OH extinction was omitted) and the total amount of NFT present in each fraction was calculated. The beginning and end fractions were assayed for liquid chromatography purity and the desired rich cut fractions were combined. The pH of the combined rich cuts was determined by both pH meter and bromothymol blue indicating solutions and was adjusted to pH 7.2-7.4 if necessary. The combined rich cuts (3-4 1.) were then assayed by W and the total formamidine content was determined, 15-16 g., 75% yield from the column. The rich cuts were concentrated on the reverse osmosis unit at C 10 C as far as possible, then the concentration to 33 g./l. was completed on the circulatory evaporator at less than 280C. A total volume of about 500 ml. concentrate was obtained. Step D. Crystallization of N-Formimidoyl Thienamycin The concentrate from the previous step is adjusted to 7.3, if necessary, and N-formimidoyl thienamycin content assayed by W, was about 85-90%. The concentrate was filtered through a'intered glass funnel (medium porosity) into a large Erlenmeyer flask. Five volumes (H2200 ml.) of 3A ethanol was filtered into the concentrate and the solution was stirred at room temperature for 10 minutes and at 0 0C for 12-24 hrs. The crystals were filtered by suction filtration and washed with 0.1 volume (-ç250 ml.) of 0 C 80% 3A ethanol followed by 1/25 volume (100 ml.) of 3A ethanol at room temperature. The crystals were dried in vacuo for 12-24 hrs. to give approximately a 40% overall yield of N-formimidoyl thienamycin (10-12 g.). Analytical results on a 50 g. blend of Nformimidoyl thienamycin, prepared as above, are as follows: C, theory 45.42%; found, 45.82% H, theory 6.03%; found, 5.72% N, theory 13.24%; found, 13.108 S, theory 10.10%; found, 10.14% residue on ignition, predicted 0.5, found 0.47%; [&alpha;]D25 = 89.4 , T.G. = 6.8%, W Zitmax 300 MM, E% = 328. DETAILED DESCRIPTION OF THE INVENTION DIPEPTIDASE INHIBITORS The chemical substances which selectively inhibit the metabolism of the dipeptidase [E.C.3.4.13.11Z, also called wdipeptidase inhibitors", include chemical compounds which are Z-2 acylamino-3-monosubstituted propenpates having the following formula EMI10.1 wherein R2 and R3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms. In either of these hydrocarbon radicals R2 and R3 up to 6 hydrogens may be replaced by halogens, or a non-terminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter. A terminal hydrogen in R3 can also be replaced by a hydroxyl or thiol group, which may be acylated, such as with an alkanoyl acid of 1-8 carbon atoms, or carbamoylated, including alkyl and dialkyl carbamate derivatives; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted alkyl amino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as a terminal amino acid grouping. R2 is preferably a branched alkyl or cycloalkyl radical (C310), with a limitation that the carbon adjacent to the carbonyl cannot be tertiary. is hydrogen, loweralkyl (C1¯6) or dialkylamino alkyl (e.g., -CH2012N(C2H5)2, -CH2CH(CH3)N(CH3)2. Some of the compounds with formula II above have asymmetric forms. Racemic Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid has been resolved. The activity resides in the dextrorotatory isomer, which has the S-configuration. Within the definition of R2, the following sub-groups are included: R4 II A wherein R4 is a straight, branched, or cyclic hydrocarbon radical of 3-10 carbon atoms which may be substituted as specified above in the definition of R2; R5R6 II B wherein Ras is cycloalkyl of 3-6 carbon atoms and R6 is either 1 or 2 alkyl substituents which may be joined to form another ring on the cycloalkyl group, or R5 and R6 may be substituted as specified above in the definition of R2; R7R8 II C wherein R7 is an alkylene group of 1-3 carbon atoms and R8 is cycloalkyl of 3-6 carbon atoms which may be substituted as specified above in the definitions of R2 and R3; within these sub-groups, the following specific compounds are included: II A: : Z-2-isovaleramido-2-pentenoic acid; methyl Z-2-isovaleramido-2-butenoate; Z-2-isovaleramido-2-butenoic acid; Z-2-benzamido-2-butenoic acid; Z-2- (3,5 ,5-trimethylhexanamido)-2-butenoic acid; Z-2-cyclobutanecarboxamido-2-butenoic acid; Z-2- cyclopropanecarboxamido-2-butenoic acid; Z-2cyclopropanecarboxamido-2-pentenoic acid; Z-2 (3-methylvaleramido ) -2-butenoic acid; Z-2-cycloheptanecarboxamido-2-butenoic acid; Z-2-nonanamido-2butenoic acid; Z- 2-cyclohexanecarboxamido- 2-butenoic acid; Z-2-(4-methylvaleramido)-2-butenoic acid; Z- 2-t-butylacetamido-2-butenoic acid; Z-2-octanamido2-butenoic acid; Z-2-butyramido-2-butenoic acid; Z-2-valeramido-2-butenoic acid; Z- 2-valeramido- 2- pentenci c acid; Z-2-cyclopentanecarboxamido-2- butenoic acid; Z-2-(6-methylheptanamido)-2-butenoic acid; Z-2-hexanamido-2-butenoic acid; Z-2-(3,7 dimethyloctanamido)-2-butonoic acid; Z-2- (3,7- dimethyl- 6-octenamido) - 2-butenoic acid; Z-2-(5chlorovaleramido)-2-butenoic acid; Z-2-(3-chlorobenzoylamido)-2-butenoic acid; Z-2-(2-chlorobenz amido) - 2-butenoic acid; Z-2-nonanamido-2-butenoic acid; Z-2-(6-bromohexanamido)-2-butenoic acid; Z-2 (3,3-dimethylpropenamido)-2-butenoic acid; Z-2benzamido-2-cinnamic acid; Z-2-benzamido-2-pentenoic acid; Z- 2-benzamido-5-methoxy-2-pentenoic acid; Z-2-benzamido-2-hexenedioic acid; Z-2-isovaleramido2-octenoic acid; Z-2-isovaleramido-2-cinnamic acid; Z-2-isovaleramido-2-hexenedioic acid; Z-2-cyclo propanecarboxamido-2-cinnamic acid; Z-2-cyclopropanecarboxamido-2-hexenedioic acid; Z-2- (5- methoxy-3-methylvaleramido) -2-butenoic acid; Z-2 ethylthioacetanido-2-butenoic acid; Z-2-(2,2-dichlorocyclopropanecarboxamido)-2-butenoic acid; Z-2 (2-ethylhexanamido)-2-butenoic acid; Z-2-di-n pròpylacetamido-2-butenoic acid; II B: Z-2- (2 ,2-dimethylcyclopropanecarboxamido)- 2-butenoic acid; (+)-Z-2-(2,2-dimethylcyclopropane- carboxamido)-2-butenoic acid; Z-2- (2,2-dimethyl- cyclopropanecarboxamido)-2-pentenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid; Z-2- (2 ,2-dimethylcyclopropanecarboxamido)- 2-hexenoic acid; Z-2- (2, 2-dimethylcyclopropane- carboxamido)-2-cinnamic acid; Z-2- (2 ,2-dimethyl- cyclopropanecarboxamido)-5-methoxy-2-pentenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-4,4,4- trifluoro-2-butenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-3-(2-chlorophenyl)propenoic acid; Z-2- (2 , 2-dimethylcyclopropanecarboxamido) -2- hexenedioic acid; Z-2-(2-ethylcyclopropanecarboxamido)-2-butenoic acid; Z-2-(2,2-diethylcyclo propanecarboxamido)-2-butenoic acid; Z-2- (2,2- diethylcyclopropanecarboxamido) -2-pentenoic acid; Z-2- (2-isopropyl-2-methylcyclopropanecarboxamido) - 2-butenoic acid; Z-2-(2-methylcyclohexanecarboxamido)2-butenoic acid; Z-5-cyano-2-(2,2-dimethylcyclopro- panecarboxamido)-2-pentenoic acid; Z-5-(N,N-dimethylcarbamoyl)-2-(2,2-dimethylcyclopropanecarboxamido)- 2-pentenoic acid; Z-2-(2,2-dimethylcyclopropanecar boxamido) - 5-methanesul fonyl- 2-pentenoic acid; Z- 2- (2 ,2-dimethylcyclopropanecarboxamido)-5-ethoxy- carbonyl-2-pentenoic acid; Z-2-(2-methylcyclo propanecarboxamido)-2-butenoic acid; methyl Z-2- (2,2-dimethylcyclopropanscarboxamldo)-2-butenoatet ethyl Z-2-(2,2-dimethylcyclopropanecarboxamido)-2- butenoate; 2-dimefhylamincethyl ester of Z-2- (2,2- dimethylcyclopropanecarboxamido)-2-butenoic acid; 3-diethylaminopropyl ester of Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-pentenoic acid; Z-2 (2,3-dimethylcyclopropanecarboxamido)-2-butenoic acid; Z-2-(3,3-dimethylcyclobutanecarboxamido)-2- butenoic acid; Z-2-(2-spirocyclopentanecarboxamido)2-butenoic acid; Z-2-(2-t-butyl-3,3-dimethylcyclo- propanecarboxamido)-2-buSenoic acid; Z-2- (2,2- dimethylcyclopropanecarboxamido)-4-methyl-2- pentenoic acid; Z-2- (2-t-butylcyclopropane- carboxamido)-2-but2noic acid; Z-2- (2-phenylcyclo- propanecarboxamido) -2-butenoic acid; Z-3-cyclohexyl- 2-(2,2-dimethylcyclopropanecarboxamido)propenoic acid; Z-5-carboxy-5-(2,2-dimethylcyclopropane- carboxamido)-4-pentenamidine; Z-5-dimethyl amino-2- (2,2-dimethylcyclopropanecarboxamido)-2-pentenoic acid; Z-3-cyclopropyl-2-(2,2-dimethylcyclopropane- carboxamido)propenoic acid; Z-2-(2,2-dimethyl- cyclopropanecarboxamido)-2,5-hexadienoic acid; Z-2 (2,2-dimethylcyclopropanecarboxamido)-4-phenyl-2- butenoic acid; Z-2-(2,2-dimethylcyclopropane- carboxamido)-6-mercapto-2-hexenoic acid; Z 2-(2,2-dimethylcyclopropanecarboxamido)-5-methyithfo- 2-pentenoic acid; 2-2-(2,2-dimethylcycopropse- carboxamido)-5-phosphono-2-pentenoic acid; Z-2 (2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-5- phenyl-2-pentenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-nonenoic acid; Z-2- (2,2- dimethylcyclopropanecarboxamido) -2 -decenoi c acid; Z-2- (2, 2-dimethylcyclopropanecarboxamido) -2-tn- decenoic acid; Z-2-(2,2-dimethylcyclopropanecarboxamido)-6-methoxy-2-hexenoic acid (and 5-methoxy2-pentenoic acid); Z-2-(2,2-dimethylcyclopropane carboxaraido) -6-methyl-2-heptenoic acid; Z-4cyclohexyl-2-(2,2-dimethylcyclopropanecarboxamido)2-butenoic acid; II C: Z-2-cyclobutylacetamido-2-butenoic acid; Z-2-cyclopentylacetamido-2-butenoic acid; Z-2cyclohexylacetamido-2-butenoic acid; Z-2-(4-cyclo hexylbutyramido) -2-butenoic acid; Z-2-cyclopropyl acetamido-2-buenoic acid; Z-2-cyclopropylacetamido2-pentenoic acid; Z-2- (3-cyclopentylpropionamido) - 2-butenoic acid; Z-2-(3-cyclohexylpropionamido)2-butenoic acid; Z-2-(4-(2-thienyl)-butyramido)-2butenoic acid; Z-2-(4-phenylbutyramido)-2-butenoic (D,L--lipoamido)-2-pentenoic acid; Z-2-(D,L-- lipoamido)-2-cinnamic acid; Z-2-(3-(2-tetrahydrofuryl)-propionamido)-2-butenoic acid. Particularly preferred substituents within the definition of R2 above include the 2,2-dimethylcyclopropyl and the 2,2-dichlorocyclopropyl groups. Within the definition of R3, pÅarticularly preferred groups of compounds include N-alkyl (1-9 carbons) and N-methyl (1-9 carbons), having a terminal substituent which is a quaternary nitrogen, amine derivative, or amino acid derived group. By the term "quaternary nitrogen" is meant a tetrasubstituted or heteroaromatic nitrogen which is positively charged. An ammonium moiety, substituted with hydrocarbon groups having 1-7 carbon atoms, which can be the same or different, is signified. By the term "amino derivative" is meant a group such as amino, acylamino, ureido, amidino, guanidino and alkyl derivatives thereof. By the term "amino acid derived group" is meant a moiety such as cysteinyl (-SCH2CH(NH2)COOH) or sarcosyl (-N(CH3)CH2COOH) in which a hydrogen joined to O, N or S of known amino acids is replaced. Particularly preferred compounds from the most preferred groups of substituents of R2 and R are those wherein R2 is 2,2-dimethylcyclopropyl or 2,2-dichlorocyclopropyl, and R3 is a hydrocarbon chain of 3 to 7 carbon atoms without a terminal substituent, or having a terminal substituent which is trimethylammonium, amidino, guanidino, 2-amino-2carboxyethylthio, or ureido. Names of specific examples of these include: Z-2- (2, 2-dimethylcyclopropanecarboxamido) -8- trimethylammonium hydroxide- 2-octenoic acid inner salt; Z- 2- (2, 2-dichlorocyclopropanecarboxamido) - 8- tnmethylammonium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-dimethylcyclopropanecarboxamido)-8- araidino-2-octenoic acid; Z-2- (2, 2-dimethylcyclopropanecarboxamido) -8- guanidino-2-octenoic acid; Z-2- (2, 2-dimethylcyclopropanecarboxamido) -8- ureido-2-octenoic acid; Z-8-(t2-amino-2-carboxyethylthio)-2-(2,2 dimethylcyclopropanecarboxamido) -2-octenoic acid; ; Z-2- (2, 2-dimethylcyclopropanecarboxamido) -2- octenoic acid (racemic and dextrorotatory forms); and Z-2- (2, 2-dichlorocyclopropanecarboxamido) -2- octenoic acid. The Z configuration (J.E. Blackwood et al., J. Am. Chem. Soc., 90, p. 509 (1968)) is assigned to the above compounds on the basis of their NMR spectra by analogy with the work of A. Srinavasan et al. [Tetrahedron Lett., 891 (1976)]. Although these compounds of Formula II, when R1 is H, are described and named as the free acids, it will be apparent to one skilled in the art that various pharmaceutically acceptable derivatives such as alkali and alkaline earth metal, ammonium, or amine salts, or the like can be employed as equivalents thereto. Salts such as the sodium, potassium, calcium, or tetramethylammonium salts are suitable. Some of the compounds of Formula II are novel compounds which are claimed in a copending U.S. application, U.S. SN 927,212, filed on July 24, 1978, now ¯¯¯¯¯¯¯¯¯, and in U.S. SN , ¯¯¯¯¯¯¯, filed concur- rently herewith, and which do not form part of this invention. As mentioned above, the thienamycin-type compound is used in combination with the dipeptidase inhibitor. METHODS OF TESTING AND USING THE INVENTION As noted, disposition studies with thienamycin, its natural analogs and its semi-synthetic derivatives have revealed a major metabolic degradation pathway of elimination in the various species examined (mouse, rat, dog, chimpanzee, Rhesus monkey). The extent of metabolism is reflected in low urinary recovery and short plasma half-lives. The nature of this degradation was demonstrated to be lactam cleavage by the renal dipeptidase (E.C.3.4.13.11), described first by Bergaann, M. and Schleich, H., Z. Physiol. Chem., 205 65 (1932); see also Greenstein, C.P., Advances in Enzymology, Vol. VIII, Wiley-Interecience, (1948), New York, and Campbell, B.J.; Lin, Y-C., Davis, R.V. and Ballew, E., "The e Purification and Properties of Particulate Renal Dipeptidase", Biochim. Biophys. Acta., 118, 371 (1966). In order to demonstrate the ability of the compounds of Formula II to suppress the action of the renal dipeptidase enzyme, an in vitro screen procedure was followed. This measured the ability of compounds to inhibit hydrolysis of glycyldehydro- phenylalanine (GDP) by a solubilized preparation of dipeptidase isolated from hog kidneys The procedure is as follows: to a 1 ml. system containing 50 AM *MOPS" (3-(N-morpholino)propanesulfonic acid) buffer, pH 7.1, is added 5g of lyophilized enzyme, and the test compound at a final concentration of O.lmM. After a five minute incubation at 370C, GDP is added to a final concentration of 0.05mM. Incubation is continued for 10 minutes, at 370C and hydrolysis of GDP is measured by the change in optical density with time at 275 nm. Inhibition of the enzyme is gauged by comparison to a standard run containing no inhibitor and is expressed as the inhibitor binding constant, Ki. This is the concentration of the inhibitor which achieves 50% inhibition of enzyme. The substrate GDP is employed in preference to thienamycin in this screen because it has a much higher maximal velocity of hydrolysis by renal dipeptidase, thereby reducing the amount of enzyme required. Both GDP and thienamycin have a similar affinity for renal dipeptidaset furthermore, K.'s of inhibitors tested have been identical for the two substrates. In addition to this in vitro screen procedure, an in vivo screen was followed to measure the test compound's ability to inhibit metabolism as reflected by increase in urinary recovery of thienamycin from the mouse. The procedure involves co-administration of the test compound by the intravenous or subcutaneous route at a dose-rate of 10-100 mg/kg, with 10 mg/kg thienamycin. Thienamycin recovery in the urine over a 4 hour period is then compared with its recovery in a control group to which test cMposd was not coadministered. Urinary recovery of thienamycin was measured in all cases with the use of cylinder or diac diffusion assay, conducted in a inner described in U.S. Patent 3,950,357, This bioaszzy, with Staphylococcus aureus ATCC 653@ U the test organism, has a useful respond range from 0.04 pg/ml to 3.0 g/ml. The combination of the inhibitor and the thienamycin class compound can be in the form of a pharmaceutical composition containing the two compounds in a pharmaceutically acceptable carrier. The two can be employed in amounts so that the weight ratio of the thienamycin class compound to inhibitor is 1:3 to 30:1, and preferably 1:1 to 5:1. The components can also be separately admini- stered. For instance, the thianamycin class compound can be administered intramuscularly or intravenously in amounts of 1-100 mg/kg/day, preferably 1-20 mg/kg/day, or 1-5 mg/kg/day, in divided dosage forms, e.g., three or four times a day. The inhibitor can be separately administered, orally, intramuscularly, or IV, in amounts of 1100 mg/kg/day, or preferably 1-30 mg/kg/day, or 1-5 mg/kg/day. The amounts of the two components administered during one day ideally are within the ratio limits denoted above. The most preferred dosage levels presently known to applicants is as a single dose, of two crystalline compounds, one being N-formimidoyl thienamycin and the other being (+) Z-2-(2,2 dimethylcyclopropanecarboxamido) -2-octenoic acid, coadministered in a sterile aqueous IV injection form (sodium salt), at a level of 150 mg. of the thienamycin and either 75 or 150 mg of the octenoic acid. This dose is given to humans (each assumed to weigh about 80 kg.) from 1 to 4 times a day, or 2-8 mg/kg/day of the thienamycin class compound and 1-8 mg/kg/day of the inhibitor. The components, whether administered separately or together are employed in pharmaceutically acceptable carriers such as conventional vehicles adapted for oral adminstration such as capsules, tablets, or liquid solutions or suspensions. The components separately or together, can also be dissolved in a vehicle adapted for administration by injection. Suitable formulations for oral use, may include diluents, granulating agents, preservatives, binders, flavoring agents, and coating agents. The example of an oral use composition in the combination of active ingredients, or the acid component alone, intermixed in the dry pulverulent state with gelatin, starch, magnesium stearate, and alginic acid, and pressed into a tablet. As noted above, the presently known preferred method is parenteral administration of the thienamycin class compound and either co-parenteral administration or oral administration of the inhibitor compound. Examples which illustrate this invention follow. SECTION 1. EXAMPLES ILLUSTRATINC ACTIVITY EXAMPLE 1 In Vitro Test Data A 1 ml. system of 50 mM "MOPS" buffer, pH 7.1, is used. To this is added 5 g of the pig renal enzyme and an amount of the test compound to bring its final concentration to 0.1 mb; After a five minute incubation at 370C, an amount of GDP is added to bring its final concentration to 0.05 mM. The system is again incubated for 10 minutes, at 370 C. Hydrolysis of GDP is measrred by its change in optical density with time at 276 nm. Inhibition of the enzyme is gauged by comparison to a standard run containing no inhibitor and is presented as percent inhibition. The Ki is a constant indicating the concentration of inhibitor necessary to produce 509 inhibition of enzyme. It is a calculated value obtained from running multiple in vitro assays, as above, at concentratlons resulting in inhibition below and above the 50% inhibition point. The results are presented in Table I. TABLE I EMI23.1 <tb> <SEP> coo. <tb> cnde <SEP> 11 <SEP> 1 <SEP> 2 <tb> Compunds <SEP> )'COfl <tb> Dipepr4dase <SEP> 3 <SEP> 2 <SEP> 1flh1bttofl <tb> <SEP> XnhjbLtcr <SEP> I <SEP> I <tb> at <SEP> ¯¯¯ <SEP> 10 <SEP> ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ <tb> <SEP> 1 <SEP> CU1CH3 <SEP> 013 <SEP> 9e <SEP> 0.10 <tb> <SEP> CH3 <tb> <SEP> 21 <SEP> CH3 <SEP> < <SEP> SS <SEP> 0. <SEP> 39 <tb> <SEP> CH3 <tb> <SEP> 013 <SEP> CH3 <SEP> < <SEP> C3 <SEP> 100 <SEP> 0.12 <tb> <SEP> CH3 <tb> <SEP> 2b <SEP> CS3 <SEP> + > U33 <SEP> 19.B <tb> <SEP> 3 <SEP> 013 <SEP> X <SEP> 3 <SEP> 92 <SEP> 1.7 <tb> <SEP> ,CH3 <tb> <SEP> 4 <SEP> CX2Ca3 <SEP> CR2-CH <SEP> 57 <SEP> 3.2 <tb> <SEP> cg3 <tb> <SEP> 5 <SEP> C113 <SEP> -ckl2CN-Cil2C{CQ3} <SEP> 3 <SEP> SI <SEP> 4.4 <tb> <SEP> CH3 <tb> <SEP> 6 <SEP> CH3 <SEP> g <SEP> CH3 <tb> <SEP> 01 <tb> *Compounds 2, 2a, and 2b arc the racemic, dextrorotatory and levorotatory form@ respectively. TABLE I, cont'd. EMI24.1 <tb> Dip <SEP> 111 <SEP> %:jbiofl <SEP> xi <tb> Inhibitor <SEP> M <SEP> t <tb> <SEP> L <tb> <SEP> /43 <tb> <SEP> 7 <SEP> CH3 <SEP> -CH2-CH <SEP> gl <SEP> s <tb> <SEP> Otj <tb> <SEP> S <SEP> CS3 <SEP> < <SEP> FizzSO <tb> <SEP> 9 <SEP> CH3 <SEP> -CHa <SEP> 4 <SEP> 63 <SEP> 6.6 <tb> 10 <SEP> CH3 <SEP> 4 <SEP> 97 <SEP> 9 <tb> 11 <SEP> CH3 <SEP> -CEz <SEP> tH-CX;CH3 <SEP> 32 <SEP> . <SEP> 10 <tb> <SEP> CH3 <tb> EMI25.1 <tb> Djp.ptldaao <tb> Znhjbjtor <SEP> R2 <SEP> Inhibition <tb> <SEP> art <SEP> 10 <SEP> N <SEP> 10 <SEP> M <tb> <SEP> 12 <SEP> - <SEP> {cH2 <SEP> ) <SEP> 4CH2 <SEP> Cc11 <SEP> .03 <tb> <SEP> 13 <SEP> -(cM2)5b1+(CH3)3 <SEP> C1 <tb> <SEP> Cl <tb> <SEP> 14 <SEP> -(CH2)5U <SEP> (C83)3 <SEP> c"3 <SEP> 1.11 <tb> <SEP> .CH3 <tb> <SEP> CH <tb> <SEP> 15 <SEP> - <SEP> (012) <SEP> 5-llH-C-NH <SEP> cN3 <tb> <SEP> CH3 <tb> <SEP> 16 <SEP> - <SEP> (CH2 <SEP> ) <SEP> QI2 <SEP> (013)2 <tb> <SEP> ,ie <tb> <SEP> H <SEP> <tb> <SEP> 17 <SEP> -(CM2)-S-012-C-CO <tb> <SEP> 3 <SEP> 3 <SEP> 0.21 <tb> TABLE I, cont'd. EMI26.1 <tb> <SEP> --------- <SEP> -,------- <SEP> <tb> DLpptid <SEP> Rj <SEP> ,t2 <SEP> at <SEP> 10 <SEP> X <tb> <SEP> lnhibitor <SEP> R3 <SEP> x <tb> ¯¯¯¯¯¯¯¯ <SEP> ¯¯¯¯¯¯¯ <SEP> 3 <SEP> ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ <SEP> 75 <SEP> ¯¯¯¯¯¯¯¯¯¯¯¯¯ <SEP> 20 <tb> <SEP> 18 <SEP> CH.3 <SEP> < 2Clc$3) <SEP> 3 <SEP> 75 <SEP> 20 <tb> <SEP> 19 <SEP> Ct1 <SEP> -(CBz' <SEP> EYJ <SEP> 72 <SEP> 2s72 <tb> <SEP> 70 <SEP> Ca3 <SEP> ¯ <SEP> { <SEP> ) <SEP> 2ql3 <SEP> 69 <SEP> 30 <tb> <SEP> 21 <SEP> CH3 <SEP> (°g2) <SEP> 3 <SEP> t0 <SEP> 68 <SEP> 30 <tb> <SEP> 22 <SEP> CH3 <SEP> 0(2 <SEP> L <SEP> *4 <SEP> 22 <tb> TABLE I, cont'd. EMI27.1 <tb> jpoptda.. <SEP> nhbition <tb> Dipaptidas <SEP> 3 <SEP> 2 <tb> Inhibitor <SEP> jt3 <SEP> It <SEP> lo''nn <tb> <SEP> at <SEP> 10 <SEP> n <tb> <SEP> 23 <SEP> CH3 <SEP> (CM2) <SEP> 3CH3 <SEP> 64 <SEP> 32 <tb> <SEP> 24 <SEP> CH3 <SEP> 0 <SEP> 59 <SEP> 30 <tb> <SEP> 25 <SEP> CH3 <SEP> -{CE2)4CH(CH3)2 <SEP> 57 <tb> <SEP> 26 <SEP> CH3 <SEP> 22 <SEP> CE2CH2-0 <SEP> 56 <tb> <SEP> 27 <SEP> CH3 <SEP> -CH2cH2 <SEP> 3 <SEP> 54 <tb> <SEP> 2a <SEP> CH3 <SEP> -CH2 <SEP> {CH) <SEP> 3CH3 <SEP> 54 <SEP> - <SEP> 39 <tb> TABLE I, cont'd. Dipeptidase Inhibitor R Rê @Inhibition xi at 10-4M ( M) 29 CH3 -(CH2)5CH3 49 30 CH3 -CH(CH2CH3)CH2CH2CH2CH3 33 31 CH3 -CH(CH2CH2CH3)2 13 32 CH3 -CH(CH3)2 31 TABLE I, cont'd. EMI29.1 <tb> Dt:iiP0ttdtoa <SEP> 1 <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> 12 <SEP> (rnlbfrion <SEP> 1 <tb> <SEP> nhibLtar <SEP> t <SEP> 10-X <tb> <SEP> at <SEP> 10 <SEP> N <tb> <SEP> 33 <SEP> bCH2CH2 <SEP> A <SEP> 90 <SEP> 5 <tb> <SEP> 34 <SEP> CH3 <SEP> -CH2-CH < 2CH20CH3 <SEP> g <tb> <SEP> CH3 <tb> <SEP> 35 <SEP> CH3 <SEP> CH2CH2CH2Cl2CR2lr <SEP> 70 <SEP> 19 <tb> <SEP> Ca3 <SEP> CH2CH2CH2CH2C1 <SEP> U <SEP> 20 <tb> <SEP> 37 <SEP> Cs3 <SEP> cR2cH2al2 <SEP> t3 <SEP> 72 <SEP> 11 <tb> <SEP> CH3 <SEP> wq <SEP> 90, <SEP> 6.5 <tb> <SEP> C(CH3) <SEP> 3 <tb> TABLE I, cont'd. EMI30.1 <tb> Dfpprid <SEP> Rj <SEP> 3 <SEP> Inhibitioa <SEP> 2 <tb> ZflhibLtor <SEP> I <SEP> I <SEP> ptidse <tb> at <SEP> R3 <SEP> 1t2 <SEP> tlnhibitXon <SEP> Xi <tb> ,,,,,,,,,,,,,,,,,,,,,,,,, <SEP> ¯ <tb> <SEP> 39 <SEP> cM3(CH2)4 <SEP> cH2-CR(CR3)2 <SEP> 95 <SEP> 2.6 <tb> <SEP> 40 <SEP> CH3 <SEP> CR2CR3 <SEP> 100 <SEP> 0.45 <tb> <SEP> I <tb> <SEP> 41 <SEP> (CH3) <SEP> 2CH <SEP> CH3 <SEP> 3 <SEP> 9B <SEP> 0.54 <tb> <SEP> CH3 <tb> <SEP> 42 <SEP> CH3 <SEP> be <SEP> CR2CR3 <SEP> 99 <SEP> 0. <SEP> B6 <tb> <SEP> CR2CH3 <tb> <SEP> 43 <SEP> CH3 <SEP> Zq <SEP> 96 <SEP> 1.6 <tb> <SEP> CH2CH3 <tb> TABLE I, cont'd. EMI31.1 <tb> D & <SEP> 3 <SEP> 3 <SEP> ptSdso <SEP> x <tb> <SEP> loibitOr <SEP> R3 <SEP> t <SEP> 10 <SEP> }t <SEP> X <tb> <SEP> ¯¯¯¯ <SEP> t <SEP> 10 <SEP> N <tb> <SEP> 44 <SEP> CH3 <SEP> < t <SEP> CB(Olj)l <SEP> 95 <SEP> 3 <tb> <SEP> CH3 <tb> <SEP> 45 <SEP> CH3CH2 <SEP> 8 <SEP> CH3 <SEP> ga <SEP> 0.11 <tb> <SEP> CH3 <tb> <SEP> 46 <SEP> Ph <SEP> T <SEP> C83 <SEP> 100 <SEP> 0.62 <tb> <SEP> 013 <tb> <SEP> 47 <SEP> 013013013 <SEP> < p <SEP> CH3 <SEP> ! <SEP> o. <SEP> ll <tb> <SEP> fQ13 <tb> <SEP> 013 <tb> <SEP> 41 <SEP> 01013 <SEP> CH3 <SEP> 97 <SEP> 0.23 <tb> <SEP> CH3 <SEP> al3 <tb> <SEP> 013(013)3 <SEP> 8 <SEP> CH3 <SEP> 100 <SEP> 0.11 <tb> <SEP> CH <tb> <SEP> 3 <tb> TABLE I, cont'd. EMI32.1 <tb> DzinPPjtij0 <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> - <SEP> %Znh1bjtofl <tb> <SEP> Inhibitor <SEP> a3 <SEP> t2 <SEP> t <SEP> 10 <SEP> XM <SEP> ¯¯ & Mt <tb> InhLbLtot <SEP> ¯¯¯¯¯¯¯¯¯¯¯ <SEP> 10 <SEP> ¯¯¯¯¯¯ <SEP> ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ <SEP> N <SEP> ¯¯¯ <SEP> N <tb> <SEP> SO <SEP> cH3(CH2)4 <SEP> < <SEP> CH3 <SEP> 100 <SEP> 0.17 <tb> <SEP> QTj <tb> <SEP> 51 <SEP> il00C0E2CH2 <SEP> t <SEP> CH3 <SEP> 98 <SEP> 0.145 <tb> <SEP> CH3 <tb> <SEP> 52 <SEP> 0 < 12 <SEP> lw <SEP> C83 <SEP> 100 <SEP> 0.19 <tb> <SEP> Qlj <tb> <SEP> 53 <SEP> thCH2CH2 <SEP> 97 <SEP> C <SEP> 3 <SEP> 96 <SEP> 0.33 <tb> <SEP> Cflj <tb> <SEP> 54 <SEP> CH3SCH2CH2 <SEP> 9 <SEP> CH3 <SEP> gg <SEP> 0.12 <tb> <SEP> CH3 <tb> <SEP> 55 <SEP> 0(31020(20(2 <SEP> 9 <SEP> C <SEP> 3 <SEP> 96 <SEP> 0.5 <tb> <SEP> CH3 <tb> EMI33.1 <tb> D1tnPPjt1jdt:O <SEP> ,t3 <SEP> \Inhlblclon <SEP> *i <tb> lnhibitor <SEP> ,3 <SEP> t2 <SEP> t <SEP> lo <SEP> 4 <SEP> ,M} <tb> at <SEP> 10 <SEP> M <SEP> (M <tb> 56 <SEP> al3XQ2)5 <SEP> q- <SEP> 013 <SEP> 98 <SEP> 0.149 <tb> <SEP> CH3 <tb> 57 <SEP> CHJ(CHI)C <SEP> cH3 <SEP> 0.092 <tb> <SEP> CH3 <tb> <SEP> 58 <SEP> CH3XCH2)9 <SEP> q <SEP> CH3 <SEP> 0.14 <tb> <SEP> CN3 <tb> S9 <SEP> PhCNz <SEP> qB <SEP> 013 <SEP> 9B <SEP> 0.44 <tb> <SEP> CH3 <tb> 60 <SEP> CH30gC82} <SEP> 3 <SEP> 9 <SEP> CH1 <SEP> 0.2B <tb> <SEP> Ql3 <tb> EMI34.1 <tb> Dipoptldasa <tb> Dip <SEP> ptid <SEP> e <SEP> R3 <SEP> t2 <SEP> tlnhibitson <SEP> ti <tb> <SEP> at <SEP> t <SEP> t <SEP> 10 <SEP> M <tb> <SEP> 61 <SEP> CM3OC?i2CM2 <SEP> air <SEP> 99 <SEP> 0.32 <tb> <SEP> CH) <tb> <SEP> 62 <SEP> (cH3)3CCH2 <SEP> 9 <SEP> CH3 <SEP> 0.34 <tb> <SEP> CHJ <tb> <SEP> 63 <SEP> (C)i3)2C11CH2012 <SEP> < ; <SEP> Q3 <SEP> 9S <SEP> 0.15 <tb> <SEP> 013 <tb> <SEP> 64 <SEP> B20C(CH2)j <SEP> 013 <SEP> 99 <SEP> 0.048 <tb> <SEP> CH3 <tb> <SEP> cs <SEP> T-7 <SEP> qw <SEP> CH3 <SEP> 0.39 <tb> <SEP> CH3 <tb> EXAMPLE 2 In Vivo Test Data An in vivo assay on the mouse was conducted as follows: 20 g Charles River CD, female mice were injected subcutaneously with the chosen dose of the chemical inhibitor. About two minutes later, the dose of thienamycin was given intravenously. A control of thienamycin above was also conducted. The level of thienamycin in the urine as a % of dose was measured using a bioassay technique. Results are found in Table II. The two test compound numbers are those from Table I. Compound 7 is 2-isovaleramido-2-butenoic acid; compound 10 is Z- 2- cyclopropylcarboxamido- 2-butenoic acid. TABLE II EMI35.1 <tb> Compound <SEP> Dose, <SEP> mg/kg <SEP> Dose, <SEP> mg/kg <SEP> % <SEP> Urinary <tb> <SEP> Compound <SEP> Thienamycin <SEP> Recovery <SEP> of <tb> <SEP> Thienamycin <SEP> <tb> <SEP> 7 <SEP> 50 <SEP> 10 <SEP> 53 <tb> <SEP> 7 <SEP> 10 <SEP> 10 <SEP> 53 <tb> <SEP> 10 <SEP> 50 <SEP> 10 <SEP> 56 <tb> Control <SEP> ¯¯¯¯ <SEP> 10 <SEP> 25-30 <tb> EXAMPLE 3 The compounds 2-isovaleramido-2-butenoic acid, Compound 7, and Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-butenoic acid, compounds were studied, in more detail in vivo in combination with thienamycin (TEM), in the mouse. The general test procedure was similar to that of Example 2. Results are summarized in Table III and Table IV. EXAMPLE 4 In another mouse study, the systemic antibacterial activity of thienamycin was enhanced approximately three-fold by coadministering 2-isovaleramido-2-butenoic acid, see Table V. TABLE V: Effect of Co-administared 2-Isovaleramido-2-butanoic acid On the Syst@mic Efficacy of Thienamycin on the Treatment of Staphalococcus aureus Infections ED50, mg/kg THM aloft. 0.2 +100 mg/kg inhibitor 0.06 TABLE III: Effect of Co-administered 2-Isovaleramidobutenoic Acid compound 7) on tha Urinary Recovery of Thienamycin jb the Mouse(a) EMI38.1 <tb> <SEP> Route(b) <SEP> mg/kg <SEP> Dose <SEP> Urinary <SEP> Recovery <tb> Compound <SEP> 7 <SEP> THM <SEP> Compound <SEP> 7 <SEP> THM <SEP> of <SEP> THM, <SEP> % <tb> <SEP> - <SEP> IV <SEP> or <SEP> SC <SEP> - <SEP> 10 <SEP> 30#5 <tb> <SEP> SC <SEP> SC <SEP> 0.3 <SEP> 10 <SEP> 33 <tb> <SEP> SC <SEP> IV <SEP> 2 <SEP> 10 <SEP> 42 <tb> <SEP> SC <SEP> SC <SEP> 2 <SEP> 10 <SEP> 47 <tb> <SEP> SC <SEP> IV <SEP> 10 <SEP> 10 <SEP> 53 <tb> <SEP> SC <SEP> SC <SEP> 50 <SEP> 10 <SEP> 54 <SEP> <tb> <SEP> SC <SEP> IV <SEP> 50 <SEP> 10 <SEP> 53 <tb> <SEP> SC <SEP> SC <SEP> 80 <SEP> 10 <SEP> 59 <SEP> <tb> <SEP> SC <SEP> SC <SEP> 100 <SEP> 10 <SEP> 81 <SEP> <tb> (a) 20 g Charles liver. CD1 f@@ale mice (b) Co-administared TABLE IV: Effect of Co-administ@red z-2-(2,2-Dimethylcyclopropanecarboxamide)- but@@@ic acid (Compound 2) @@ Urinary R@@@very of Thienamycin in the @@@@@(@) EMI38.2 <tb> <SEP> Route <SEP> (b) <SEP> mg/kg <SEP> Urimary <SEP> R@@@@@ry <SEP> <tb> Compound <SEP> 2 <SEP> TMM <SEP> Compound <SEP> 2 <SEP> TMM <SEP> TMM, <SEP> @ <tb> - <SEP> SC <SEP> - <SEP> 10 <SEP> <SEP> 3@#5 <SEP> <tb> K <SEP> SC <SEP> 0.1 <SEP> 10 <SEP> 35 <tb> SC <SEP> SC <SEP> 0.3 <SEP> 10 <SEP> 40 <SEP> <tb> SC <SEP> SC <SEP> 1 <SEP> 10 <SEP> <SEP> 46 <SEP> <tb> SC <SEP> SC <SEP> 10 <SEP> 10 <SEP> 60 <SEP> <tb> SC <SEP> SC <SEP> 30 <SEP> <SEP> 10 <SEP> 73 <SEP> <tb> (a) 20 g Charles River. CD1 f@@als mice (b) Co-administ@r@d EXAMPLE 5 A male beagle was used for a study of the effect of dipeptidase inhibitors on the urinary recovery of N-formimidoyl thienamycin. In a control study, the dog was given 5 mq/kg IV of the N-formimidoyl thienamycin without inhibitor. A second experiment used the same amount of N-forsimidoylthienamycin, but also administered Z-2-isovaleramido-2-butenoic acid in 3 doses, each providing 20 mg/kg of the compound. The first dose was administered just after injection of the N-formssmidoylthienamycin, the second at 40 min. and the third at 60 min. The third study employed a single dose (2 mg/kg) of Z-2-(2,2-dimethylcyclopropanecarboxvmido)-2-butenoic acid, administered just before injection of the Nformimidoyl thienamycin. The results are in Table VI. TABLE VI: Urinary Recovery 3 Hours Following the Administration of N-formimidoylthienamycin (5 mg/kg IV) in a Male Beagle Test Compound % Urinary Recovery N-fornimidoyl thienamycin 7.8 plus Z-2-isovaleramido-2-butenoic acid 46 plus Z-2- (2 ,2-dimethylcyclopropane carboxamido)-2-butenoic acid 53 SECTION 2. EXAMPLES ILLUSTRATING CHEMICAL PREPARATIONS The inhibitor compounds are novel compounds claimed in a copending application. These compounds are made by condensing directly the appropriate 2-keto acid and amide: EMI41.1 wherein R2 and R3 are as defined. The general reaction conditions involve mixing approximately 1-4:1 parts of the acid to the amide in an inert solvent such as toluene or methyl isovalerate and heating at reflux with azeotropic removal of water for from 3-48 hours, preferably 5-24 hours. The solution when cooled normally yields the product in crystalline form, but the product can also be isolated using a base extraction process. The product can be recrystallized by using generally known techniques. An optional modification of this procedure requires an additional small amount of p-toluenesulfonic acid as catalyst during the reaction. Another route to the novel inhibitor compounds uses an a-amino acid, t-butyl ester in reaction with an acid chloride: EMI41.2 This reaction takes place in the presence of base, such as triethylamine, in a solvent such as methylene chloride. The resulting N-acylated product (VII) is then oxidized by treatment with t-butyl hypochlorite followed by addition of sodium methoxide. This yields the 2-methoxy derivative (VIII) and/or its elimination product, the a,ss-unsaturated ester (IX). Further treatment with anhydrous hydrochloric acid converts either VIII or IX (or the mixture of both) to the desired a,ss-unsaturated free acid (II). EMI42.1 EMI42.2 Some compounds wherein R3 has a terminal substituent which is an amino, quaternary nitrogen, thiol or carboxyl, derivative can be made most conveniently from an intermediate having a bromo substituent instead of the desired terminal substituent, followed by condensation with the desired thiol, amino, acid, or the like. More detail about preparation of the compounds is found in the following examples. EXAMPLE 6 Z-2-Isovaleramido-2-butenoic Acid A solution of 1.07 g (10.5 mmole) of 2-ketobutyric acid and 0.71 g (7.0 mmole) of isovaleramide in 15 ml of toluene was stirred under reflux with collection of H20 in a small Dean-Stark trap. After 5 hrs, the solution was cooled, resulting in fairly heavy crystallization. After standing, the solid was collected on a filter and washed with toluene and then with CH2C12. Yield of white crystals = 0.47 g, mp 172-174 (slight prelim. softening). me e material was recrystallized from diisopropyl ketone. Tlc (4:1 toluene-AcOH) now showed only a faint trace of, the other isomer. Yield of white crystals = 0.32 g (25*), mp 175 (slight prelim. softening). NMR indicated essentially exclusively Z-isomer. Anal. (C9H15N03) Calcd. Found C 58.36 58.59 H 8.16 8.55 N 7.56 7.43 EXAMPLE 7 Z-2- (2 ,2-Dimethylcyclopropanecarboxamido) -2- pentenoic acid A solution of 1.74 g (15 mmole) of 2-ketovaleric acid and 1.13 g (10 mmole) of 2,2-dimethylcyclopropanecarboxamide in 20 ml of toluene was refluxed with stirring with collection of H20 in a small Dean-Stark trap. After 20 hrs. the solution was cooled and treated with a gentle stream of N2. Before much of the solvent had evaporated, crystallization was induced by scratching. After standing, the solid was collected on a filter and washed with toluene and some Et2O. Yield of white crystals - 0.63 g (30%), mp 154.5L 55.50 (slight prelim. softening). Tlc (4:1 toluene-AcOH) showed only an extremely faint trace of the other isomer. NMR was consistent with the Z-configuration. Anal. (C11H17N03) Calcd. Found C 62.53 62.86 H 8.11 8.27 N 6.63 6.75 EXAMPLE 8 Z-2- (3-Cyclopentylpropionamido)-2-butenoic acid A solution of 1.41 g (10 mmole) of 3-cyclopentylpropionamide and 1.53 g (15 mmole) of 2-ketobutyric acid was stirred and refluxed under a small Dean-Stark trap. After 8 hrs. the solution was cooled, resulting in heavy crystallization. The solid was collected on a filter and washed with toluene and CH2C12. Yield of white crystals = 1.44 g, mp 180.51820 (prelim. softening). The material was recrystallized from methyl ethyl ketone. Yield of white needles - 0.63 g (28%), mp 184-1850 (slight prelim. softening). Tlc (4:1 toluene-AcOH) now showed a single spot, and NMR indicated essentially pure Z-isomer. Anal. (C12H19N03) Calcd. Found C 63.97 63.99 H 8.50 8.67 N 6.22 6.27 EXAMPLE 9 Z-2- (2-Ethylhexanamido)-2-butenoic acid 10 g. of 2-ethylhexanoyl chloride was added dropwise with stirring to 25 ml of cold conc. NH 4OH solution, resulting in immediate precipitation. The mixture was allowed to stir for 2 hrs., then filtered, and air dried to give 6.5 g. of amide. 1.4 g (10 mmole) of the above compound and 1.5 g of ketobutyric acid (15 mmole) were refluxed in 25 ml toluene for 15 hrs with removal of water. The reaction mixture was cooled and partly evaporated with a stream of N2. Crystallization of product occurred after standing for 3 hrs. The crystals were collected, washed 3x with toluene, and air dried. There was isolated 1.13 g (50%) of product, mp l60-l62. NMR was in accord with the assigned structure and indicated < 5% E isomer. Tlc (4:1 toluene-AcOH) showed a single spot. Anal. (C12H21N03) Calcd. Found C 63.40 63.63 H 9.30 9.43 N 6.16 5.88 EXAMPLE 10 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-2- butenoic acid 1.53 g (15 mmoles) of 2-ketobutyric acid, 1.13 g (10 mmoles) of 2,2-dimethylcyclopropanecarboxamide and 20 ml of toluene stirred at reflux for 10 hours. After cooling the crystalline solid was filtered and washed with toluene (3x 10 ml) and dried to give 1.06 g of product, mp 140-1410C. Tlc (4:1 toluene-AcOH) showed essentially one spot and the NMR spectrum fit the desired structure. Recrystallization from EtOAc gave after drying 0.533 g of product mp 142-143.5 , homogeneous by tlc. Anal. (C10Hl5N 3) Calcd. Found C 60.90 60.92 H 7.67 7.71 N 7.10 7.38 EXAMPLE 11 Z-2- (2, 2-Dimethylcyclopropanecarboxamido)-2-hexene- dioic acid A mixture of 1.0 g. of 2,2-dimethylcyclopropanecarboxamide, 2.4 g. of 2-ketoadipic acid and 25 ml. of methyl isovalerate was heated under reflux for 4 hrs, with removal of H2O by a modified Dean Stark trap containing molecular sieves (4A). After standing at room temperature overnight, the crystal line precipitate was filtered, washed with ether and recrystallized from ethyl acetate to give 0.23 g. of product, m.p. 163-165o. The NMR spectrum was consistent with the desired structure. Anal. (C12Hl7Nos) Calcd. Found C 56.46 56.20 H 6.71 6.83 N 5.49 5.32 EXAMPLE 12 Z-2- (2 ,2-Diethylcyclopropanecarboxamido) -2- butenoic acid A mixture of 2.3 g of 2-ketobutyric acid, 2.0 g of 2,2-diethylcyclopropanecarboxamide, and 25 ml of toluene was heated under reflux for 16 hrs with removal of H20 by a modified Dean-Stark trap containing molecular sieves (4A). No product precipitated upon cooling. Ether (25 ml) was added and the mixture was extracted with saturated NaHCO3 (3 times). The combined extracts were acidified with concentrated HCl. The gummy precipitate crystallized when triturated with water. Recrystallization from ethyl acetate gave 0.31 g of product, m.p. 129-300. The NMR spectrum was consistent with the desired structure. Anal. (C12H19NO3) Calcd. Found C 63.98 64.01 H 8.50 8.62 N 6.22 6.21 EXAMPLE 13 2-(2,2-Dimethylcyclopropanecarboxamido)-2-hexenoic acid Step A: DL-Norleucine -but ester General procedure of R. R3eske, J. Org. Chem. 28, p. 1251 (1963). To a suspensipn of 9.82 q (75 mmole) of DLnorleucine in 80 ml of dioxane in a 500 ml. pressure bottle cooled in an ice bath was added slowly (with swirling) 8 ml of concentratad H2S04. The resulting mixture was cooled in a dry ice bath as 80 ml of liquid isobutylene was added. The mixture was allowed to warm to room temperuture and shaken under autogenous pressure for - 23 hrs. After most of the isobutylene had been vented off, the slightly hazy solution was cooled in ice and then added to a cold mixture of 400 ml of 1N NaOH and 500 ml of Et2O. After shaking in a separate funnel, the layers were separated, and the aqueous fraction was washed with an additional 100 ml of Et2). The Et2O solution was shaken with 150 ml of 0.5 E HC1. The acidic aqueous fraction was treated with 2.5 N NaOH until strongly basic and than shaken with 250 ml of Et2O. The Et2O solution was dried (MgSO4), filtered, and concentrated on the rotovac. After prolonged pumping on high vacuum over a steam bath, final yield of clear, colorless residual oil = 9.04 g (65%). NMR now showed only z trace of dioxane. TLC (9:1 CEC13-MeOS) showed a single spot. Step B: N- (2 ,2-Dimethylcyclopropanecarbonyl)-DL- norleucine t-butyl ester To a solution of 8.98 g (48 mmole) of DLnorleucine t-butyl ester and 5.05 g (50 mmole) of triethylamine in 100 ml of CH2C12 stirred in an ice bath under a drying tube was added dropwise (over a period of 75 min.) a solution of 6.39 g (48 mmole) of 2,2-dimethylcyclopropanecarbonyl chloride (M. Elliot and N.R. James, British Patent No. 1,260,847 (1972)) in 50 ml of CH2C12. Precipitation of Et3N HC1 occurred during the addition, especially toward the end. As the ice gradually melted, the mixture was allowed to warm to room temperature. After 16 hrs, the mixture was shaken with 200 ml of 0.5 N HC1. The CH2C12 fraction was washed with an additional 200 ml of 0.5 N HC1, then with 2 x 200 ml of 0.5 N NaOH, and finally 200 ml of H20. The CH2C12 fraction was dried with MgSO4, treated with charcoal, and filtered through Celite. The filtrate was concentrated on the rotovac (finally under high vacuum). Yield of light orange residual oil - 11.93 g (88%). Tlc (2:1 hexane-EtOAc) showed a single spot. NMR and IR were in accord with the assigned structure. After standing for several days, the unused porition of this material crystallized: m.p. 52 - > 650. Step C: t-Butyl 2-(2,2-dimethylcyclopropanecarboxa mido)-2-methoxyhexanoate Based on procedure of H. Poisel and V. Schmidt, Chem. Ber., 108 p. 2547 (1975). To a solution of 6.37 g (22.5 mmole) of N (2 ,2-dimethylcyclopropanecarbonyl) -DL-norleucine t-butyl ester in 35 ml of Et2O stirred at room temperature under N2 in the dark was added 2.69 ml (2.45 g, 22.5 mmole) of t-butyl hypochlorite. After 15 min., a solution of sodium methoxide prepared by dissolving 0.52 g (22.6 mmole) of sodium in 35 ml of MeOH was added. Stirring was continued at ambient temperature under N2 in the dark. After 16.5 hrs., the precipitated NaCl was filtered off. The filtrate was diluted with Et2O and washed successively with 3 x 50 ml of 0.5 N HC1, 50 ml of saturated Nazi03, and 2 x 50 ml of H2 0. The E20 phase was dried over MgSO4 and filtered. The filtrate was concentrated on the rotovac. The pale, golden-yellow residual oil (6.45 g) was subjected to preparative high pressure liquid chromatography, resulting in the separation and isolation of 273 mg and 496 mg of the two diastereomers of t-butyl 2- (2, 2-dimethylcyclopropane- carboxamido)-2-methoxyhexanoate (respective mp's 114-1180 and 124-125.5 ) as well as 1.97 g of a single isomer (apparently Z) of t-butyl 2-(2,2 dimethylcyclopropanecarboxamido) -2-hexenoate (colorless oil). Step D: 2(2 ,2-Dimethylcyclopropanecarboxamido)-2- hexenoic acid A solution of 0.84 g (3.0 mmole) of t-butyl 2-(2,2-dimethylcyclopropanecarboxamido)-2-hexenOate in 10 ml of Et2O saturated with anhydrous HCL was allowed to stand at room temperature under a drying tube. After 17 hrs, the solution was evaporated, and the residual gum was dissolved in 10 ml of saturated NaHCO3. This solution was washed with an additional 15 ml of 0.5 N HC1, then dried (NqSO4), filtered, and concentrated to give a viscous oil. The oil was crystallized from toluene. Yield of white crystals = 0.32 g (47%), m.p. 119 122µ. TLC (4:1 toluene-AcOH) showed a single spot. NMR indicated essentially pure isomer. (Note: Treatment of the methanol adduct, t-butyl 2-(2,2 dimethylcyclopropanecarboxamido)-2-methoxyhexenoate, with anhydrous HC1 in Et20 under similar conditions gave the same product.) EXAMPLE 14 (+)-Z-2- (2 ,2-Dimethylcyclopropanecarbonylaraino) -2- octenoic acid, sodium salt The reagents, (+) -2, 2-dimethylcyclopropane- carboxamide, 7.0 g.; 2-keto-octanoic acid ethyl ester, 14.7 g.; 50 mg. of p-toluene sulfonic acid; and 100 ml. of toluene was changed to a 250 ml. t)tree-necked flask under a Dean Stark trap containing several molecular sieve pellets. The mixture was refluxed vigorously for 27 hours. The resultant light yellow solution was cooled and concentrated in vacuo, at a water bath temperature of 450C., in the presence of water to help remove toluene. The gummy residue was suspended in 230 ml. of 2N NaOH and stirred at 300C for 3 hours; then the temperature was raised to 350C for an additional 2-1/2 hrs. until a clear solution formed. The solution was then cooled, 85 ml. methylene chloride added, and the pH adjusted to 8.5 using 4N HC1 with stirring. The organic layer was separated and discarded. The aqueous layer (366 ml.) was assayed by liquid chromatography to contain 37.2 mg/ml; 87% Z isomer. Another 85 ml. portion of CH2C12 was then added and pH adjusted to 4.5 with stirring. The organic layer was separated and the aqueous layer reextracted with 50 ml. of CH2C12, with the pH again adjusted to 4.5. Combined organic extracts were dried over Na2SO4, filtered, and concentrated to a gum. This residue was dissolved in 150 ml. isopropanol and 15 ml. water and the pH adjusted to 8.2 with 2N NaOH. The resulting solution was concentrated to an oily residue which was flushed with isopropanol until it turned to a crystalline solid, indicating that most water had been removed. It was crystallized from 120 ml. of isopropanol, (cooled in ice for 1 hour) filtered, and washed with 50 ml. cold isopropanol followed by copious amounts of acetone. It was dried at 600C/0.1 mm/2 hours to yield 10.74 g (63.2%) crystalline material, having essentially a single peak in liquid chromatography, m.p. 241-2430C. The starting material, (+)-2,2-dimethylcyclopropanecarboxamide is most conveniently prepared by resolution of the D,L acid, followed by reaction with oxalyl chloride and then ammonia to give the resolved amide. One way of making the starting material is as follows: 23.1 g. of D,L-2,2-dimethylcyclopropanecarboxylic acid was suspended in 33 ml H20 and the pH adjusted to 8.0, using 50% NaCH, about 10 ml. To this was added a solution of 38.4 g quinine in a mixture of 60 ml. methanol and 30 ml. H2 to which had been added about 8ml of concentrated HC1 in another 30 ml. H20 to give a pH of 7.1. (This was actually a solution of quinine hydrochloride.) These solutions were added all at once, with stirring. The gummy crystalline material which formed was heated to give two clear layers and again stirred vigorously while cooling to give a crystalline product. This product was permitted to stand over two days at room temperature. It was then filtered, washed with 2 x 10 ml water, and 2 x 10 ml 50% methanol, and air dried with suction. The yield of crude quinine salt was 44.8 g (48.7% 20 yield) monohydrate, m.p. 113-116µC, having a [&alpha;]D of -94.3, C = 1.0; CHC13. This material was recrystallized from acetone to yield 24.35 g, m.p. 127-1300C. This purified quinine salt was converted to the acid by reaction with aqueous base and chloroform, followed by acid, to yield (96%) 3.9 g having [al20 of +146.0 . This acid was converted to the amide as follows: A charge of 30.5 g (+)acid was added over 5-10 minutes through a dropping funnel to chilled (10 C) oxalyl chloride, 54 ml., containing 1 drop dimethylformamide. This was stirred overnight at ambient temperature. A clear solution was observed, which was added to 100 ml. methylene chloride to dilute. Excess oxalyl chloride was removed by concentrating and the mixture flushed twice with methylene chloride. The resultant solution was diluted with an equal volume of methylene chloride, and added continuously through a dropping funnel to about 100 ml. anhydrous liquid ammonia which was diluted with 100 ml methylene chloride. A dry ice-acetone cooling bath was used during the addition. When all was added, the cooling bath was removed and the mixture stirred at room temperature for about 1/2 hour. The mixture was filtered, to remove precipitated ammonium chloride, and concentrated to dryness. The crude weight was 26.6 g. (88%). It was redissolved in excess hot ethyl acetate and filtered through a preheated sintered glass funnel to separate from trace NH4Cl. Excess ethyl acetate was atmospherically distilled off. When half the volume remained, 130 ml of heptane were added, and ethyl acetate was continued to be distilled off, until the boiling point started to rise (to near 800C; much of product had already crystallized out). Heat was removed, and the mixture let cool gradually to about 300C, then cooled with an ice bath to 0-50C for about 1/2 hour. The product was recovered as nice silverywhite crystalline flakes, washed with 3 x ethyl acetate/hexane mixture, 1/1.5 and air dried to constant weight. It weighed 23.3 g (77.1% yield overall, 87.6% recovery from crude), m.p. - 1351380C (varies with rate of heating). Angle of rotation was determined by dissolving 0.0543 g in 10 ml chloroform, [&alpha;]20 - +100.90. D EXAMPLE 15 Z-2- (2, 2-Dichlorocyclopropanecarboxamido) -2- butenoic acid Step A: 2 ,2-Dichlorocyclopropanecarboxamide A 7.1 g sample of 2,2-dichlorocyclopropanecarbonyl chloride (U.S. Patent 3,301,896, issued January 31, 1967) was added dropwise to 75 ml of concentrated ammonium hydroxide with vigorous stirring. The temperature of the reaction mixture was maintained below 10*C with an ice bath. The mixture was stirred in the ice bath for 30 min., then at room temperature for 1 hr. The aqueous ammonia was evaporated under reduced pressure (bath at 50 C). The solid residue was extracted with hot ethyl acetate (3 x 30 ml). The extracts were boiled down to 40 ml and 20 ml of hexane was added. After cooling in ice, the solid was filtered, washed with ethyl acetate-hexane (1:1) and dried to give 2.7 g of 2,2-dichlorocyclopropanecarboxamide, m.p. 144-146'. The NMR spectrum was in accord with the desired structure. Anal. (C12H5C12N0) Calcd. Found C 31.20 31.26 H 3.27 3.31 N 9.10 9.11 C1 46.04 45.79 Another 1.3 g of amid, m.p. 143-14S could be recovered from the mother liquor. Step B: z-2- (2 ,2-Dichlorocyclopropanecarboxamido)- 2-butenoic acid A mixture of 1.53 g (15 mmole) of 2-ketobutyric acid, 1.54 g (10 mmoles) o 2,2-dichlorocyclopropanecarboxamide and 10 ml of toluene was heated under reflux for 12 hrs. with removal of H20 by a modified Dean-Stark trap containing molecular sieves (4A). An additional 0.7 g of 2ketobutyric acid was added and the reaction mixture was heated under reflux for an additional 12 hrs. The mixture was 'cooled, diluted with 20 ml of toluene and extracted with saturated sodium bicarbonate (3 x 10 ml). The extracts were combined, washed with ether and acidified to pH 3 (pH meter) with concentrated hydrochloric acid. A gum precipitated which soon solidified. It was filtered, washed with water, dried and recrystallized from nitromethane to give 423 mg of Z-2-(2,2-dichloro cyclopropanecarboxamido)-2-butenogc acid, m. p. 188-189.50C. The NMR spectrum was in accord with the desired structure. Anal. (C8HgC12N03) Calcd. Found C 40.36 40.48 H 3.81 3.80 N 5.88 5.91 C1 29.78 29.53 EXAMPLE 16 Z-2- (2, 2-Dichlorocyclopropanecarboxamido) -2- octenoic acid A mixture of 1.19 g (7.5 mmoles) of 2-ketooctanoic acid, 0.77 g (5.0 mmoles) of 2,2-dichlorocyclopropanecarboxamide, and 5 ml toluene were reacted using the same procedure as in the previous example. The crude product (537 mg) was purified by conversion to the methyl ester (BF3/CH30H), preparative TLC (silica gel G, 4:1 hexane-EtOAc) and saponification of the pure Z-methyl ester (0.3M LiOH/CH3OH) to give 88 mg of Z-2-(2,2 dichlorocyclopropanecarboxamido) -2-octenoic acid as a partially crystalline gum. NMR spectrum EMI57.1 EXAMPLE 17 Z- 8-Bromo-2- (2, 2-Dimethylcyclopropanecarboxamido) - 2-octenoic acid To a suspension of 14.4 g (0.3 mole) of 50% NaH dispersion in 360 ml of toluene cooled in an ice bath and in a N2 atmosphere was added over 45 min. a solution of 146 g (0.6 moles) of 1,6dibromohexane and 57.6 g (0.3 mole) of ethyl 1,3dithiane-2-carboxylate in 120 ml of DMF. The cooling bath was removed and the mixture stirred at room temperature for 2 hrs. The reaction mixture was washed with water (3 x 210 ml), dried over MgSO4 and evaporated under reduced pressure to give 179.5 g of a yellow oil containing the desired anhydrated dithiane, 1,6-dibromohexane and mineral oil. This crude material was used in the next reaction without purification. To a suspension of 426 g (2.4 moles) of N-bromosuccinamide in 800 ml of acetonitrile and 200 ml of H20 was added over 45 min. a solution of the crude dithiane in 100 ml of acetonitrile. The temperature of the reaction mixture was maintained below 250C with an ice bath. After stirring at 200C for 10 min. the dark red reaction mixture was poured into 2 1. of hexane-CH2C12 (1:1). The solution was shaken with saturated NaHS03 (2 x 400 ml) and water (1 x 500 ml). Then 400 ml of saturated Na2 CO3 solution was added in small portions (vigorous CO2 solution). After the foaming subsided the funnel was shaken and the aqueous phase separated. The organic layer was extracted with saturated Na2C03 solution (400 ml) and water (500 ml) and dried over MgSO4. Removal of the solvent under reduced pressure gave 133.8 g of crude bromo ketoester containing 1,6-dibromohexane and mineral oil. This crude material was used in the next reaction without purification. A mixture of 133.8 g of crude bromo ketoester, 133 ml of 50% hydrobromic acid and 267 ml of acetic acid was heated at 90 0C (internal temperature) for 75 min. The dark solution was evaporated under reduced pressure until most of the acetic acid was removed. The residue was dissolved in 500 ml of ether, washed with water (2 x 100 ml) and extracted with saturated NaHCO3 (3 x 200 ml). The combined NaHCO3 extracts were extracted with ether (2 x 100 ml) and acidified with concentrated HC1. The precipitated oil was extracted with ether (3 x 200 ml). The ether extracts were washed with water (1 x 100 ml) and saturated brine (1 x 100 ml) and dried over Mugs04. Removal of the ether under reduced pressure gave 46.2 g of pure bromoketo acid. Homogeneous by T1C (silica gel, 4:1 toluene-acetic acid). The NMR spectrum was consistent with the desired product. A mixture of 46.1 g (0.194 moles) of the bromoketo acid , 17.6 g (0.156 mole) of 2,2-dimethylcyclopropanecarboxamide and 450 ml of toluene was heated under reflux for 13 hrs., with collection of water in a small Dean-Stark trap. After cooling, the clear reaction mixture was extracted with saturated NaHCO3 solution (4 x 100 ml). The combined extracts were washed with ether (2 x 100 ml) and then the pH was adjusted to 3.5 (pH meter) by addition of concentrated HC1. An oil precipitated which soon crystallized. The solid was filtered, washed well with water and dried. Recrystallization from acetonitrile gave 22.5 g of Z-8-bromo-2-(2,2- dimethylcyclopropanecarboxamido) -2-octenoic acid, m.p. 151-1530C. Homogeneous by TLC (4:1 tolueneacetic acid). The NMR spectrum was consistent with the desired structure. Anal. (C14H22BrN03) Calcd Found C 50.61 50.66 H 6.67 6.96 N 4.22 4.45 Br 24.05 23.95 The followingbromo compounds were prepared using the same procedure: Z-6-Bromo-2-(2,2-dimethylcyclopropanecarboxamido) hexenoic acid; Z-7-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)- heptenoic acid; Z-9-Bromo-2- (2, 2-dimethylcyclopropanecarboxamido) - 2-nonenoic acid; Z-10-Bromo-2-(2,2-dimethylcyclopropanecarboxamido) decenoic acid; Z-8-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)- octenoic acid. EXAMPLE 18 Z-8-Dimethylamino-2- (2, 2-dimethylcycloproane- carboxamido)-2-octenoic acid A solution of 664 mg (2 mmoles) of Z-8-bromo 2- (2, 2-dimethylcyclopropanecarboxamido) -2-octenoic acid in 10 ml of 40% aqueous dimethylamino was allowed to stand at room temperature for 4 hrs. The solution was poured onto a 3.5 x 20 cm column of Dowex 50W-x8 (100-200 mesh, H+) ion exchange resin and column eluted with water until the effluent was no longer acidic (-200 ml). The column was then eluted with 300 ml of 2N ammonium hydroxide. The effluent was evaporated under reduced pressure to give 600 mg of a colorless glass. This material was dissolved in 3 ml of ethanol, filtered, and added dropwise to 200 ml of rapidly stirred acetone. A gummy solid precipitated which crystallized upon stirring for two days. The solid was filtered, washed with acetone, and dried to give 445 mg of Z 8-dimethylamino-2- (2, 2-dimethylcyclopropanecarboxa- mido)-2-octenoic acid as a colorless, hygroscopic crystals, m.p. 101-1120C, Homogeneous by TLC (silica gel, in BuOH, HOAc, H20, 4:1:1). NMR spectrum was consistent with desired structure. Anal. (C16H28N203.H20) Calcd. Found C 61.12 61.03 H 9.62 9.28 N 8.91 8.67 The following 8-amino derivatives were prepared using essentially the same procedure, "DCC" means 2 (2,2-dimethylcyclopropanecarboxamido). Z- 10 -Dimethylamino-DCC- 2-decenoic acid; Z-8-Amino-DCC-2-octenoic acid; Z-8-Dimethylamino-DCC-2-octenoic acid; Z-7-Dimethylamino-DCC-2-heptenoic acid; Z-DCC-7- (N-methylpiperazinyl)-2-heptenoic acid; Z-DCC- 8-pyrrolidino-2-octenoic acid; Z-DCC-8- (N-methylpiperazinyl)-2-octenoic acid; Z-8-Allylamino-DCC-2-octenoic acid; Z-DCC-8-piperidino-2-octenoic acid; Z-DCC- 8-propargylamino-2 -octenoic acid; Z- 8-N- [1-Deoxy- (1-methylamino) -D-glucityl -DCC-2- octenoic acid; Z-8- (1-Adamantylamino) -DCC-2-octenoic acid; Z-8-Diallylamino-DCC-2-octenoic acid; Z-8-DCC-8-(2-hydroxyethylmethylamino)-2-octenoie acid; Z-8-[(Carboxylmethyl)methylamino]-2-(2,2-DCC)-2- octenoic acid; ; Z-2- (2, 2-DCC) -8-diethylamino-2-octenoic acid; 2-2-(2,2-DCC)-8-ttris-(hydroxymethyl)methylaminol-2O octenoic acid Z-2-(2,2-DCC)-10-(N-methylpiperazinyl)-2-decenoic acids Z-2-(2,2-DCC)-8-[1-(phosphono)ethylaminol-2-octenoic acid; EXAMPLE 19 z-2- (2 ,2-Dimethylcyclopropanecarboxamido) -8-methyl- thio-2-octenoic acid Astream of CH3SH gas was bubbled through a solution of 162 mg (3 mmoles) of sodium methoxide in 5 ml of methanol for 10 min. with cooling in an ice bath. The solution was allowed to warm to room temperature and 332 mg (1 mmole) of Z-8-bromo-2 (2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid was added. The solution was heated under reflux for 30 min. in a N2 atmosphere. Most of the methanol was evaporated under reduced pressure, the residue was dissolved in 10 ml of water and acidified with 2.5 N HCl. The precipitated oil was extracted with ether (3x). The ether extracts were washed with water, saturated brine and dried over MgSO4. Removal of the ether under reduced pressure gave a colorless oil that crystallized upon standing. It was recrystallized from ether-hexane to give 178 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)-8- methylthio-2-octenoic acid, m.p. 82-840C. Homogeneous by TLC (toluene-acetic acid, 4:1). The NMR spectrum was in accord with the desired structure. Anal. (C15H25NO3S) Calcd. Found C 60.18 60.36 H 8.42 8.68 N 4.68 4.59 S 10.69 10.87 The following compounds were prepared by similar methods, "DCC" means 2- (2, 2-dimethylcyclopropane- carboxamido). Z-DCC- 8-ethoxythiocarbonylthio-2-octenoic acid; Z-DCC-8-(1-methyl-5-tetrazolylthio)-2-octenoic acid; Z-DCC-7-{[(methoxycarbonyl)methyl]thio}-2-heptenoic acid; Z-8-Acetylthio-DCC-2-octenoic acid; Z-7- [ (2-Amino-2-oxoethyl) thio]-DCC-2-heptenoic acid; 6- (L-2-Amino-2-carboxyethylthio) -2- (2, 2-DCC-2- hexenoic acid; Z-8-(Carbomethoxymethylthio)-2-(2,2-DCC)-2- octenoic acid; Z-6- (Carbomethoxymethylthio)-2- (2 ,2-DCC)-2-hexenoic acid; Z-2-(2,2-DCC)-6-(phosphonomethylthio)-2-hexenoic acid. EXAMPLE 20 Z-2-(2,2-Dimethylcyclopropanecarboxamtido)-8-trimethyt ammonium hydroxide-2-octenoic acid inner salt A solution of 996 mg (3 mmoles) of Z-8-bromo-2- (2 ,2-dimethylcyclopropanecarboxamido) -2-octenoic acid in 15 ml of 25% aqueous trimethylamine was allowed to stand at room temperature for 3 hrs. The reaction mixture was poured onto a 2 x 25 cm column of IRA-410 (50-100 mesh, OH ) ion exchange resin and eluted with water until the effluent was no longer basic. me e effluent was evaporated under reduced pressure to give 800 mg of a colorless glass. This material was dissolved in 20 ml of ethanol, filtered and diluted with 600 ml of acetone. After standing at room temperature overnight the crystalline solid which deposited was filtered, washed with acetone and dried to give 720 mg of z-2-(2,2-dimethylcyclo- propanecarboxamido)-8-trimethylammonium hydroxide2-octenoic acid inner salt as hygroscopic crystals, m.p. 220-2220C. Homogeneous by TLC (silica gel, in BuOH, HOAc, H20, 4:1:1). NMR spectrum was consistent with desired structure. Anal. (C17H30N203) Calcd Found C 65.77 65.78 H 9.74 9.98 N 9.02 8.92 Other quaternary derivatives were prepared using essentially the same procedure; these are Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -8-trimethyl- ammonium hydroxide-2-ctenoic acid inner salt; Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8- pyridinium hydroxide-2-octenoic acid; Z-2- (2,2- Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8- (2-hydroxyethyldimethylammonium hydroxide)-2- octenoic acid inner salt; Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -10- trimethylammonium hydroxide-2-decenoic acid inner salt; z- 8- (Benzyldimethylammcnium hydroxide) -2- (2,2 dimethylcyclopropanecarboxamido)-2-octenoic acid inner salt; ; Z-10- (Benzyldimethylarrrmonium hydroxide)-2-(2,2 dimethylcyclopropanecarboxamido) -2-decenoic acid inner salt; Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -9- trimethylammonium hydroxide- 2-nonenoi c acid inner salt; Z-8- (2-Dimethylaminoethyldimethylarnmonium hydroxide) 2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid inner salt; Z-2-(2,2-Dichlorocyclopropanecarboxamido)-8-trimethyl- ammonium hydroxide-2-octenoic acid inner salt; ; EXAMPLE 21 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8- formamidino-2-octenoic acid A 350 mg sample of Z-8-amino-2-(2,2-dimethyl cyclopropanecarboxamido)-2-octenoic acid was dissolved in 10 ml of water and the pH adjusted to 8.5 with 2.5N NaOH. A total of 947 mg of benzyl formimidate hydrochloride was added at room temperature in small portions over 20 min. while the pH was maintained between 8-9 by addition of 2.5N NaOH. After stirring at room temperature for 30 min., the cloudy reaction mixture was extracted with ether (3X) and applied to a 2 x 2.5 cm column of a G5OW-X4 (Na+, 200-400 mesh) resin. After elution with water, the fractions containing the product were pooled and evaporated under reduced pressure. This material was dissolved in water and applied to a 2 x 25 cm column of a G1X8 (HCO3, 200-400 mesh) resin. After elution with water, the fractions containing pure product were pooled and evaporated under reduced pressure. The residue was dissolved in a few ml of warm ethanol, filtered, and added dropwise to 200 ml of ether with rapid stirring. Filtration and washing with ether gave 243 mg of Z-2- (2, 2-dimethyl- cyclopropanecarboxamido) - 8-formamidino-2-octenoic acid as an amporphous solid. Homongeneous by TLC (n-BuOH, HOAc, H20; 4:1:1). The NMR spectrum was in accord with the desired structure. Anal. (C15H25N303.l/3H20) Calcd. Found C 59.69 60.04 H 8.59 8.64 N 13.92 13.57 The following amidino compounds were prepared using the similar procedures: Z-8-Acetamidino-2- (2, 2-dimethylcyclopropanecar- boxamido)-2-octenoic acid; Z-8-Benzylamidino-2-(2,2-dimethylcyclopropanecar boxamido) -2-octenoic acid; Z-2- (2 ,2-Dimethylcyclopropanecarboxamido) -10- formamidino-2-decenoic acid; Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -8- (2 -imidazoyl-2-yl-amino) -2-octenoi c acid. EXAMPLE 22 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8- guanidino-2-octenoic acid To a solution of 2 mmoles of guanidine (prepared from 432 mg of guanidine sulfate and 630 mg of barium hydroxide octahydrate) in 7 ml of water was added 332 mg (1 mmole) of 8-bromo-2-(2,2dimethylcyclopropanecarboxamido)octenoic acid, and the solution was heated at 700C in a nitrogen atmosphere for 1 hr. The reaction mixture was applied to a 2 x 25 cm column of Dowex 50W-X8 (H+; 100-200 mesh). After elution with water the fractions containing the product were pooled and evaporated under reduced pressure. The residue was dissolved in several ml of warm ethanol and added dropwise to 100 ml of ether with rapid stirring. Filtration and washing with ether gave 107 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)- 8-guanidino-2-octenoic acid as an amorphous electrostatic powder. Homogeneous by TLC (n-BuOH, HOAc, H2O; 41:1). NMR (D20, NaOD): 6.48 # (t, lH, 3.10/(m,'2H, CHN-), 2.10 J,(m, 2H, ='CH2), 1.17 / (s, 3H, EMI67.1 ,The following guanidino compound was prepared using the same procedure: Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-(NjN- dimethylguanidino)-2-octenoic acid. EXAMPLE 23 Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -8- methyl-2-octenoic acid To a solution of 2.43 mmoles of sodium methoxide in 5 ml of methanol was added 332 mg (1 mmole) of 8 bromo-2- (2, 2-dimethylcyclopropanecarboxamido) -2- octenoic acid. The solution was heated under reflux in a nitrogen atmosphere for 1 hr. The reaction mixture was evaporated under reduced pressure, the residue dissolved in water and acidified with 2.5 N hydrochloric acid. The oil which precipitated was extracted with ether (3X). The ether extracts were washed with water, and saturated brine and dried over MgSO4. Removal of the ether under reduced pressure gave a colorless oil that crystallized upon standing. It was recrystallized from ether-hexane to give 140 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-methoxy-2-octenoic acid, m.p. 71-720C. Homogeneous by TLC (toluene-HOAc, 4:1). The NMR spectrum was in accord with the desired structure. Anal. (C15H25N04) Calcd. Found C 63.58 63.54 H 8.89 9.12 N 4.94 5.16 Using similar procedures, the following compounds were prepared: Z-8-Cyano-2-(2,2-dimethylcyclopropanecarboxamido)- 2-octenoic acid; Z-7-Cyano-2- (2, 2-dimethylcyclopropanecarboxamido) - 2-heptenoic acid; Z-9-Cyano-2- (2 ,2-dimethylcyclopropanecarboxamido) - nonenoic acid; Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -7-sulfo- 2-heptenoic acid sodium salt; Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-sulfo 2-octenoic acid sodium salt; Z-2- (2, 2-Dimethylcyclopropanecarboxamido) -8- hydroxy-2-octenoic acid; Z-8-Acetoxy-2-(2,2-dimethylcyclopropanecarboxamido) 2-octen'oic acid.

Claims: WHAT IS CLAIMED IS: 1. An antibacterial composition comprising a combination of thienamycin-type compound and a dipeptidase (E.C.3.4.13.11) inhibitor, the ratio of the thienamycin-type compound to the dipeptidase inhibitor being within the range of about 1:3 to about 30:1. 2. The composition of Claim 1 in which the combination is mixed with a pharmaceutical carrier. 3. The composition of Claim 2 in which the carrier is adapted for injection. 4. The composition of Claim I in which the thienamycin-type compound is thienamycin. 5. The composition of Claim 1 in which the thienamycin-type compound is N- formimidoylthienamycin0 6. The composition of Claim 1 in which the thienamycin-type compound is N-acetimidoylthienamycin. 7. The composition of Claim 1 in which the dipeptidase inhibitor is a compound of the following formula: EMI71.1 wherein R2 and R3 are hydrocarbon radicals in the range respectively of 3-10 and 1-15 carbon atoms; in either one of these R2 or R3 hydrocarbon chains 1-6 hydrogens may be replaced by halogens or a nonterminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R3 can also be replaced by a hydroxyl or thiol group, which may be acylated or carbamoylated; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as a terminal amino acid grouping; and R1 is hydrogen or lower alkyl (C1 6) or dialkylaminoalkyl, or a pharmaceutically acceptable cation. 8. The composition of Claim 7 in which R2 can be R4, wherein R4 is branched or cyclic hydrocarbon of 3-10 carbon atoms; -R5R61 wherein R5 is cycloalkyl of 3-6 carbon atoms and R6 is either 1 or 2 alkyl substituents which may be joined to form another ring on the cycloalkyl group or R6 is 1 or 2 chloro substituents; -R7R8, wherein R7 is alkylene of 1-3 carbon atoms and R8 is cycloalkyl of 3-6 carbon atoms; or R2 can also be a straight, branched or cycloalkyl group of 3-10 carbon atoms including alkylcycloalkyl and dialkylcycloalkyl, providing the carbon adjacent to the carbonyl cannot be tertiary. 9. The composition of Claim 7 in which R2 is 2, 2-dimethylcyclopropyl. 10. The composition of Claim 7 in which R2 is 2,2-dichlorocyclopropyl. 11. The composition of Claim 7 in which the dipeptidase inhibitor is Z-2- (2, 2-dimethylcyclo- propanecarboxamido)-2-octenoic acid.

Inventors: KAHAN, FREDERICK M., KROPP, HELMUT
Applicants: MERCK & CO. INC.
Application year: 1979
Main classification: A61K31
IPC codes: A61K31, C07F9, C07D477